STTK, US82024L1035

Shattuck Labs stock highlights SL-846 at UEG Week 2026

Published on 10/31/2026 at 02:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Shattuck Labs stock is in focus after the biotech outlined two UEG Week presentations on antibody programs. The event ran in Barcelona.

Shattuck Labs expands antibody pipeline visibility

Shattuck Labs announced two poster presentations for UEG Week 2026 in Barcelona.
One presentation covered the dual-receptor antibody candidate SL-846.
The company also presented research on TL1A immune complexes and anti-drug antibodies.
SL-325 remains Shattuck Labs' lead DR3 antagonist program for inflammatory diseases.

STTK, US82024L1035, Illustration mit AI erstellt.

Shattuck Labs announced on October 13, 2026, that it would present two posters at United European Gastroenterology Week 2026 in Barcelona. The company described the program in a Shattuck Labs release.

Two antibody programs take center stage

The moderated poster focused on SL-846, a half-life-extended bispecific antibody designed to target DR3 and IL23RA. Mahmud Hussain, Shattuck Labs' director of research and development, was scheduled to present the work on October 19.

A separate ePoster addressed soluble TL1A and anti-TL1A immune complexes. The research examined de novo TL1A production and anti-drug antibodies that cross-bind approved inflammatory bowel disease antibodies. The ePoster was scheduled to remain available throughout the October 17 to October 20 congress.

Pipeline remains clinically focused

The UEG program adds visibility to Shattuck Labs' early-stage antibody research, but the announcement does not provide clinical efficacy data or a regulatory milestone. For investors, the next material catalysts remain updates from the company's development programs and further evidence on the potential of its DR3 and TL1A approach.

What Shattuck Labs develops

Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific DR3 blocking antibodies for inflammatory and immune-mediated diseases. Its lead program, SL-325, is designed to block the TL1A/DR3 pathway more completely and durably. The company operates from Austin, Texas, and Durham, North Carolina. The company profile identifies Shattuck Labs as a focused developer of antibody therapeutics rather than a diversified pharmaceutical group.